• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Evercore Rates ABBV as Outperform - Sees 36% Upside

August 17, 2017

 (Photoe Credit - AbbVie)

 

Evercore and International Strategy & Investment Group merged together back in the fall of 2014 to create Evercore ISI, a highly regarded investment bank with a mission to "create and deliver the most useful investment research to [their] clients." Evercore ISI released an updated list of their healthcare stock ratings last night, and set an 'Outperform' rating for shares of AbbVie (NYSE:ABBV). Evercore's new price target for AbbVie is $95 per share. At the time of writing this, shares of ABBV were trading at $69.98 per share, representing a roughly 36% upside. 

 

Related: Is AbbVie a Marijuana Stock?

 

Evercore's $95 price target is the highest of analyst price targets for AbbVie. The average analyst price target for ABBV is $75.45, with the median analyst price target being $73 according to the Wall Street Journal. Currently, the lowest analyst price target for shares of ABBV is $60.

 

Related: Analyst Upgrades Shares of ZYNE to a 'Buy'

 

For more cannabinoid biotech stocks, check out our biotech marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram

 

D/M/O

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.